title: [In search of strategies for preventing brain damage as a sequela of bacterial meningitis].
abstract: Multiplication of bacteria within the central nervous system compartment triggers a host response with an overshooting inflammatory reaction which leads to brain parenchyma damage. Some of the inflammatory and neurotoxic mediators involved in the processes leading to neuronal injury during bacterial meningitis have been identified in recent years. As a result, the therapeutic approach to the disease has widened from eradication of the bacterial pathogen with antibiotics to attenuation of the detrimental effects of host defences. Corticosteroids represent an example of the adjuvant therapeutic strategies aimed at downmodulating excessive inflammation in the infected central nervous system. Pathophysiological concepts derived from an experimental rat model of bacterial meningitis revealed possible therapeutic strategies for prevention of brain damage. The insights gained led to the evaluation of new therapeutic modalities such as anticytokine agents, matrix metalloproteinase inhibitors, antioxidants, and antagonists of endothelin and glutamate. Bacterial meningitis is still associated with persistent neurological sequelae in approximately one third of surviving patients. Future research in the model will evaluate whether the neuroprotective agents identified so far have the potential to attenuate learning disabilities as a long-term consequence of bacterial meningitis.
authors.affiliation: Infektiologie, Institut für Medizinische Mikrobiologie, Universität Bern. sleib@imm.unibe.ch
authors.forename: S L
authors.initials: SL
authors.lastname: Leib
authors.forename: M G
authors.initials: MG
authors.lastname: Täuber
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use; D001925:Brain Damage, Chronic / Q000209:etiology / Q000517:prevention & control*; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D006801:Humans; D016920:Meningitis, Bacterial / Q000150:complications* / Q000188:drug therapy; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D051381:Rats
chemical_list: D000900:Anti-Bacterial Agents; D018696:Neuroprotective Agents